[PRISMS Study. Interferon-beta 1a (Rebif) in relapsing multiple sclerosis].
Hartung
H P
HP
Universitätsklinik für Neurologie, Karl-Franzens-Universität, Graz.
Flachenecker
P
P
Weilbach
F X
FX
Rieckmann
P
P
D000276:Adjuvants, Immunologic / Q000008:administration & dosage* / Q000009:adverse effects; D000328:Adult; D004185:Disability Evaluation; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D007279:Injections, Subcutaneous; D000068556:Interferon beta-1a; D016899:Interferon-beta / Q000008:administration & dosage* / Q000009:adverse effects; D008297:Male; D009103:Multiple Sclerosis / Q000628:therapy*; D009460:Neurologic Examination / Q000187:drug effects; D011446:Prospective Studies; D016896:Treatment Outcome
D000276:Adjuvants, Immunologic; D016899:Interferon-beta; D000068556:Interferon beta-1a